ClinicalTrials.gg
Active, not recruitingNCT04229056COMPEXUpdated Oct 2, 2026

COMPuter-assisted Self-training to Improve EXecutive Function

An interventional study of Computer-based cognitive rehabilitation (CBCR) and General computer-based cognitive stimulation in Parkinson Disease, Stroke and Cardiac Arrest, sponsored by Bispebjerg Hospital. Active, not recruiting at 2 sites in Denmark. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Bispebjerg Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 2, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Parkinson Disease with a site in Denmark — 12 open to participants now, 18 under way, 1 of them phase 3. Parkinson Disease · Denmark.

Planned enrollment
3rd of 33
307 · median 75
Started
2020
with 1 other
No phase
23 of 50
9 open now
Primary completion
2026-11
later than 4 of 17 live
Registered
26th of 50
by date
Lead sponsor
4 of 50
Bispebjerg Hospital

Among the 50 studies in Parkinson Disease with a site in Denmark, this one is the 3rd largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2020, is one of 23 with no phase, reaches primary completion later than 4 of the 17 other live ones, and was the 26th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

12 of the 50 studies in Parkinson Disease with a site in Denmark are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Parkinson Disease with a site in Denmark, or all of them as a file.
02

Study summary

This project explores the effects of specialized computer-based cognitive rehabilitation (CBCR) targeting executive functions in three groups of patients: Stroke, Cardiac Arrest and Parkinson's Disease. The effect of specialized CBCR is compared to generally cognitively stimulating activities on a computer

Read the detailed description

This project explores the effects of specialized computer-based cognitive rehabilitation (CBCR) targeting executive functions in three groups of patients: Stroke, Cardiac Arrest and Parkinson's Disease. The effect of specialized CBCR is compared to completing generally cognitively stimulating activities on a computer. A total of 307 patients is expected to be enrolled. All patients will complete a neuropsychological test battery assessing executive functions at inclusion, directly after the eight-week training period and at follow-up three months after the end of the intervention period. Furthermore, all patients will answer questionnaires concerning quality of life and ADL-measures at baseline, after the intervention and at follow-up. All patients will train for a period of 8 weeks, 5 times a week for 60 minutes regardless of their group allocation.

03

Conditions studied

  • Parkinson Disease
  • Stroke
  • Cardiac Arrest
  • Cognitive Dysfunction
  • Executive Dysfunction

Keywords

  • parkinson disease
  • stroke
  • cardiac arrest
  • executive dysfunction
  • cognitive dysfunction
  • computer-based cognitive rehabilitation
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • A diagnose of stroke, cardiac arrest or Parkinson's disease.
  • Aged 18 years or older.
  • Impaired working memory measured with CABPad working memory test, cut off for inclusion: 5 symbols or less backwards
  • Computer and internet access at home.
  • Providing .

Inclusion criteria specific for stroke

  • Inclusion within 6 months post-stroke
  • Stroke confirmed by clinical findings and imaging, both AIS and ICH is allowed.
  • Initial stroke severity >/= NIHSS 3.

Inclusion criteria specific for cardiac arrest

  • Inclusion within 6 months post ictus.

Inclusion criteria specific for Parkinson's disease

  • Clinical diagnosis of PD.
  • Anti-parkinsonian medical treatment (dopaminergic or other).

Exclusion Criteria:

  • Informed consent not provided
  • Other neurological or psychiatric disease which is expected to influence the patient's ability to participate in the trial according to the investigator
  • Not able to participate according to investigator

Exclusion criteria specific for stroke

  • Patients with massive anosognosia for executive dysfunction or patients with no subjective feeling of executive dysfunction (Patient sustains total denial of executive symptoms over time)
  • Patients with severe aphasia, in which it is unclear whether the patient's performance on a neuropsychological test-battery is due to aphasia and not executive dysfunction.

Exclusion criteria specific for cardiac arrest • None

Exclusion criteria specific for PD

  • Diagnosis of PD Dementia according to the MDS PD Dementia criteria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
307 participants (estimated)

Study arms

  • Experimental
    Specific computer-based cognitive rehabilitation

    154 patients will be allocated to specific computer-based cognitive rehabilitation. This group will train with 10 exercises from the cognitive rehabilitation software 'Scientific Brain training PRO'. These 10 exercises are designed to train various executive functions.

    Behavioral: Computer-based cognitive rehabilitation (CBCR)

  • Active comparator
    General computer-based cognitive stimulation

    154 patients will be allocated to general computer-based cognitive stimulation. This group will train with 10 generally mentally stimulating games on a website specifically designed for this trial. These 10 games are chosen because they are believed to have a low load on executive functions but stimulate over-all concentration and visuoperceptual abilities.

    Behavioral: General computer-based cognitive stimulation

Interventions

  • BehavioralComputer-based cognitive rehabilitation (CBCR)

    CBCR are software-programmes for computers which are clinically developed for rehabilitation of various cognitive functions.

  • BehavioralGeneral computer-based cognitive stimulation

    For this trial we have developed a webpage for general cognitive stimulation, which is designed to provide general computer-based cognitive stimulation.

06

What researchers measure

Primary outcomes

  1. CABPad Working Memory Test

    Test of working memory. The higher score the better (theoretically infinite score)

    Time frame: After the end of the intervention (8 weeks after baseline)

Secondary outcomes

  1. CABPad Working Memory Test - 3 months follow-up

    Test of working memory. The higher score the better (theoretically infinite score)

    Time frame: At follow-up visit 3 months after end of intervention

  2. Minimum Data Set-Home Care- Instrumental Activities of Daily Living (MDS-HC-IADL)

    Questionnaire concerning activities of daily living. 0-3 points on an 8-item scale, the fewer points the better.

    Time frame: At follow-up visit 3 months after the end of the intervention

  3. Trail Making A

    Test of processing speed and visual attention. The lower score the better (theoretically infinite score)

    Time frame: Directly after the intervention, eight weeks after inclusion

  4. Trail Making A

    Test of processing speed and visual attention. The lower score the better (theoretically infinite score)

    Time frame: At follow-up visit 3 months after the end of the intervention

  5. Trail Making B

    Test of divided attention, mental flexibility. The lower score the better (theoretically infinite score)

    Time frame: Directly after the intervention, eight weeks after inclusion

  6. Trail Making B

    Test of divided attention, mental flexibility. The lower score the better (theoretically infinite score)

    Time frame: At follow-up visit 3 months after the end of the intervention

  7. SDMT

    Symbol Digit Modalities Test: Test of mental speed. The higher score the better (theoretically infinite score)

    Time frame: Directly after the intervention, eight weeks after inclusion

  8. SDMT

    Symbol Digit Modalities Test: Test of mental speed. The higher score the better (theoretically infinite score)

    Time frame: At follow-up visit 3 months after the end of the intervention

  9. Phonological verbal fluency test

    Test of verbal phonological fluency. The higher score the better (theoretically infinite score)

    Time frame: Directly after the intervention, eight weeks after inclusion

  10. Phonological verbal fluency test

    Test of verbal phonological fluency. The higher score the better (theoretically infinite score)

    Time frame: At follow-up visit 3 months after the end of the intervention

  11. Categorical verbal fluency test

    Test of verbal categorical fluency. The higher score the better (theoretically infinite score)

    Time frame: Directly after the intervention, eight weeks after inclusion

  12. Categorical verbal fluency test

    Test of verbal categorical fluency. The higher score the better (theoretically infinite score)

    Time frame: At follow-up visit 3 months after the end of the intervention

  13. Fear questionnaire

    Questionnaire with 24 items concerning fear on a scale from 0 to 8 where 8 indicates a higher degree of avoidance due to fear

    Time frame: Directly after the intervention, eight weeks after inclusion

  14. Fear questionnaire

    Questionnaire with 24 items concerning fear on a scale from 0 to 8 where 8 indicates a higher degree of avoidance due to fear

    Time frame: At follow-up visit 3 months after the end of the intervention

  15. mrs: Modified Rankin Scale

    Questionnaire concerning disability on a scale from 0 (no symptoms) to 6 (dead): Higher score indicates more severe disability.

    Time frame: Directly after the intervention, eight weeks after inclusion

  16. mrs: Modified Rankin Scale

    Questionnaire concerning disability on a scale from 0 (no symptoms) to 6 (dead). Higher score indicates more severe disability.

    Time frame: At follow-up visit 3 months after the end of the intervention

  17. IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly)

    Cognitive decline in the elderly, reported by partner. A scale of 16 items from 1 (much better) to 5 (much worse). Higher score indicates more severe disability.

    Time frame: Directly after the intervention, eight weeks after inclusion

  18. IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly)

    Cognitive decline in the elderly, reported by partner. A scale of 16 items from 1 (much better) to 5 (much worse). Higher score indicates more severe disability.

    Time frame: At follow-up visit 3 months after the end of the intervention

  19. EuroQol-5 domain (EQ-5D-5L)

    Quality of life scale with 5 domains, each rated from 1-5 indicating slight to severe disability . Higher score indicates more severe disability. Completed by patient and partner

    Time frame: Directly after the intervention, eight weeks after inclusion

  20. EuroQol-5 domain (EQ-5D-5L)

    Quality of life scale with 5 domains, each rated from 1-5 indicating slight to severe disability. Higher score indicates more severe disability. Completed by patient and partner

    Time frame: At follow-up visit 3 months after the end of the intervention

  21. PDQ 39 (Parkinsons Disease Questionnaire: Only in patients with Parkinson Disease)

    Quality of Life questionnaire in patients with Parkinson's Disease. A scale with 39 items rated from 1 (never) to 5 (all the time / Can not do at all). Higher score indicates more severe disability.

    Time frame: Directly after the intervention, eight weeks after inclusion

  22. PDQ 39 (Parkinsons Disease Questionnaire: Only in patients with Parkinsons Disease)

    Quality of Life questionnaire in patients with Parkinson's Disease. A scale with 39 items rated from 1 (never) to 5 (all the time / Can not do at all). Higher score indicates more severe disability.

    Time frame: At follow-up visit 3 months after the end of the intervention

  23. Compliance

    Monitoring of total time spent training in minutes

    Time frame: Directly after the intervention, eight weeks after inclusion

  24. PHQ-9 (Patient health questionnaire 9)

    Questionnaire about health of patient with 9 items rated on a 4 point scale from 0 (not at all) to 3 (almost every day). Higher score indicates more severe disability.

    Time frame: Directly after the intervention, eight weeks after inclusion

  25. PHQ-9 (Patient health questionnaire 9)

    Questionnaire about health of patient with 9 items rated on a 4 point scale from 0 (not at all) to 3 (almost every day). Higher score indicates more severe disability.

    Time frame: At follow-up visit 3 months after the end of the intervention

  26. 2) visual analogue scale (1-10)

    After last session: how much they liked doing the training and if they would recommend the intervention to somebody else in their situation. Higher score indicates they liked the training more.

    Time frame: Directly after the intervention, eight weeks after inclusion

  27. Minimum Data Set-Home Care- Instrumental Activities of Daily Living (MDS-HC-IADL)

    Questionnaire concerning activities of daily living. 0-3 points on an 8-item scale, the fewer points the better.

    Time frame: Directly after the intervention, eight weeks after inclusion

07

Study locations

2 sites
08

References and documents

Publications

  • Svaerke K, Christensen L, Lokkegaard A, Kjaergaard J, Jacobsen JC, Engelter S, Modrau B, Quinn T, Traenka C, Sunnerhagen KS, Christensen H. The COMPEX-trial: computer-based cognitive rehabilitation to improve executive function versus unspecific training in patients after stroke, cardiac arrest or in Parkinson's disease: study protocol for a randomized controlled trial. Trials. 2026 Mar 19;27(1):310. doi: 10.1186/s13063-026-09623-5. PubMed 41857604 ↗

Individual participant data

Plan to share: Undecided — This is currently undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Nov 2026, 77 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 77 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2025 → Nov 2026 and completion Jun 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2020
First posted
Jan 14, 2020
StartActual
Jun 1, 2020
Primary completionEst.
Nov 5, 2026was Dec 2025
CompletionEst.
Feb 5, 2027was Jun 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 2, 2026
Primary completion
Dec 31, 2025→Nov 5, 2026
Oct 2, 2026
Study completion
Jun 30, 2026→Feb 5, 2027
Oct 2, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41857604 ↗
Oct 2, 2026
Sponsor
Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Rigshospitalet, Denmark
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41857604 ↗
    Primary completion Dec 31, 2025→Nov 5, 2026
    Study completion Jun 30, 2026→Feb 5, 2027
    Sponsor Collaborators added: Copenhagen University Hospital, Rigshospitalet; collaborators removed: Rigshospitalet, Denmark
    + 6 other changes: index terms, identifiers, verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04229056
Collaborators
Copenhagen University Hospital, Rigshospitalet, University of Glasgow, University of Basel, Copenhagen Trial Unit, Center for Clinical Intervention Research, Hjernesagen, Göteborg University, Aalborg University Hospital, Neurorehabilitering - Kbh, City of Copenhagen
Responsible party
Hanne Christensen (Professor, Bispebjerg Hospital) — Principal investigator
First posted
Jan 14, 2020
Start date
Jun 1, 2020
Primary completion
Nov 5, 2026 (estimated)
Completion
Feb 5, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Hanne Christensen, Professor
principal investigator · Bispebjerg Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion